These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30051341)

  • 41. Grim news for vaccine.
    AIDS Patient Care STDS; 2002 Oct; 16(10):513-4. PubMed ID: 12442739
    [No Abstract]   [Full Text] [Related]  

  • 42. Metagenomic identification of viral pathogens.
    Bibby K
    Trends Biotechnol; 2013 May; 31(5):275-9. PubMed ID: 23415279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparing virus classification using genomic materials according to different taxonomic levels.
    Wang JD
    J Bioinform Comput Biol; 2013 Dec; 11(6):1343003. PubMed ID: 24372032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral Metagenomics on Blood-Feeding Arthropods as a Tool for Human Disease Surveillance.
    Brinkmann A; Nitsche A; Kohl C
    Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27775568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An HIV vaccine--challenges and prospects.
    Johnston MI; Fauci AS
    N Engl J Med; 2008 Aug; 359(9):888-90. PubMed ID: 18753644
    [No Abstract]   [Full Text] [Related]  

  • 46. Approaches to preventative and therapeutic HIV vaccines.
    Gray GE; Laher F; Lazarus E; Ensoli B; Corey L
    Curr Opin Virol; 2016 Apr; 17():104-109. PubMed ID: 26985884
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Exploring the viral world through metagenomics.
    Rosario K; Breitbart M
    Curr Opin Virol; 2011 Oct; 1(4):289-97. PubMed ID: 22440785
    [TBL] [Abstract][Full Text] [Related]  

  • 48. No vaccine against HIV yet--are we not perfectly equipped?
    Singh M
    Virol J; 2006 Aug; 3():60. PubMed ID: 16939652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adjuvanted vaccine strategies and live vector approaches for the prevention of AIDS.
    Voss G; Villinger F
    AIDS; 2000; 14 Suppl 3():S153-65. PubMed ID: 11086858
    [No Abstract]   [Full Text] [Related]  

  • 50. Viral metagenomics.
    Edwards RA; Rohwer F
    Nat Rev Microbiol; 2005 Jun; 3(6):504-10. PubMed ID: 15886693
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Artificial antigens for HIV vaccine design.
    Expert Rev Vaccines; 2007 Jun; 6(3):301. PubMed ID: 17542744
    [No Abstract]   [Full Text] [Related]  

  • 52. DNA vaccines for HIV: challenges and opportunities.
    Hokey DA; Weiner DB
    Springer Semin Immunopathol; 2006 Nov; 28(3):267-79. PubMed ID: 17031649
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Advances in the Immunogenic Design of HIV-1 Vaccine].
    Zhang X; Wang T; Yu X
    Bing Du Xue Bao; 2016 Jan; 32(1):88-92. PubMed ID: 27295889
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metagenomic approaches for direct and cell culture evaluation of the virological quality of wastewater.
    Aw TG; Howe A; Rose JB
    J Virol Methods; 2014 Dec; 210():15-21. PubMed ID: 25264099
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diversity considerations in HIV-1 vaccine selection.
    Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
    Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ViromeScan: a new tool for metagenomic viral community profiling.
    Rampelli S; Soverini M; Turroni S; Quercia S; Biagi E; Brigidi P; Candela M
    BMC Genomics; 2016 Mar; 17():165. PubMed ID: 26932765
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design.
    Novitsky V; Rybak N; McLane MF; Gilbert P; Chigwedere P; Klein I; Gaolekwe S; Chang SY; Peter T; Thior I; Ndung'u T; Vannberg F; Foley BT; Marlink R; Lee TH; Essex M
    J Virol; 2001 Oct; 75(19):9210-28. PubMed ID: 11533184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Virology. Moving forward in HIV vaccine development.
    Letvin NL
    Science; 2009 Nov; 326(5957):1196-8. PubMed ID: 19965456
    [No Abstract]   [Full Text] [Related]  

  • 60. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus.
    Schell JB; Bahl K; Folta-Stogniew E; Rose N; Buonocore L; Marx PA; Gambhira R; Rose JK
    Virology; 2015 Feb; 476():405-412. PubMed ID: 25591175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.